COVID-19 ARDS: A Multispecialty Assessment of Challenges in Care, Review of Research, and Recommendations

Shibu Sasidharan, Vijay Singh, Jaskanwar Singh1, Gurdarshdeep Singh Madan2, Harpreet Singh Dhillon3, Prasanta K. Dash4, Babitha Shibu5, Gurpreet Kaur Dhillon6

Departments of Anaesthesiology and Critical Care, 1Internal Medicine, 2Radio-diagnosis and Imaging, 3Psychiatry and 4Pathology, Level III IFH MONUSCO, Goma, Democratic Republic of the Congo, 5Consultant Radiology, Alchemist Ojas Hospital, Panchkula, Haryana, India, 4Department of Paediatrics, 166 Military Hospital, Jammu, India

Abstract

Physicians and care providers are familiar with the management of ARDS, however, when it occurs as a sequela of COVID-19, it has different features and there remains uncertainty on the consensus of management. To answer this question on how it compares and contrasts with ARDS from other causes, the authors reviewed the published literature and management guidelines as well as their own clinical experience while managing patients with COVID-19 ARDS. For research, a PubMed search was conducted on 01.04.2021 using the systematic review filter to identify articles that were published using MeSH terms COVID-19 and ARDS. Systematic reviews or meta-analyses were selected from a systematic search for literature containing diagnostic, prognostic and management strategies in MEDLINE/PubMed. Those were compared and reviewed to the existing practices by the various treating specialists and recommendations were made. Specifically, the COVID-19 ARDS, its risk factors and pathophysiology, lab diagnosis, radiological findings, rational of recommendation of drugs proposed so far, oxygenation and ventilation strategies and the psychological ramifications of the disease were discussed. Because of the high mortality in mechanically ventilated patients, the above recommendations and findings direct the potential for improvement in the management of patients with COVID-19 ARDS.

Keywords: ARDS, COVID19, ICU

Introduction

The coronavirus disease 2019 (COVID-19) is an acute infectious disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) has labelled COVID-19 as a global infectious disease pandemic. COVID-19 is the third major outbreak caused by coronavirus in this century, with the earlier ones being severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Physicians and care providers are familiar with the management of acute respiratory distress syndrome (ARDS), however, when it occurs as a sequela of COVID-19, it has different features and there remains uncertainty on the consensus of management. To answer this question on how it compares and contrasts with ARDS from other causes, we undertook a review of the published literature (Pubmed Search on 01-04-2021, using MeSH terms “covid-19”, “pneumonia”, “ARDS”, “pathogenesis”, “epidemiology”,...
“survival”, “therapeutics”, and “complications”) and also based on our own clinical experience of managing patients with COVID-19 ARDS in DR Congo and India. This information will provide an insight to the pattern of patient response and challenges faced by the ICU teams and give a comprehensive multispeciality recommendation for circumnavigating these difficulties.

History

The World Health Organization on 31 December 2019 formally notified about a cluster of cases of pneumonia in Wuhan City, central China. By 05 January 2020, 59 cases were known and none had been fatal. Ten days later, there were 282 confirmed cases, of which four were in Japan, South Korea, and Thailand. By then, there had been six deaths in Wuhan, 51 people were severely ill, and 12 were critical. The responsible pathogen was isolated on 7 January and its genome was shared on 12 January. The causative organism of the SARS, now named as COVID-19, was a novel coronavirus, SARS-CoV-2. Today, history is continuously being rewritten, and as of 08 July 2020, there are 12M confirmed cases and 548K deaths worldwide. 168,957 new cases of COVID-19 worldwide were being confirmed daily and the death rate was over 4,147 per day. These numbers are conceivably an underestimate of the actual infected and dead because of restrictions of surveillance and testing.

Clinical Features and Classification

The patients are classified vide, WHO, and CCDC guidelines into mild, moderate, severe and critical illness on the basis of their symptoms. The details can be removed as the focus of the article is ARDS. The symptomatology is already discussed in many articles.

Definition of ARDS

The affected patients are classified vide, WHO, and CCDC guidelines with mild, moderate, severe and critical illness on the basis of their symptoms. COVID-19 ARDS (CARDS) is diagnosed when someone with a confirmed COVID-19 infection meets the Berlin 2012 ARDS diagnostic criteria, which include:

(i) acute hypoxemic respiratory failure;
(ii) presentation within 1 week of worsening respiratory symptoms;
(iii) bilateral airspace disease on chest X-ray, computed tomography (CT), or ultrasound that is not fully explained by effusions, lobar or lung collapse, or nodules; and
(iv) cardiac failure is not the primary cause of acute hypoxemic respiratory failure

Phenotypes of CARDS

CARDS is of two phenotypes and also varies in terms of management:

a. Type L - characterized by low elastance, high compliance, low lung weight, low lung recruitability, and low ventilation-to-perfusion (V/Q) ratio. This phenotype displays normal breathing but has low oxygen saturations (“silent hypoxemia” or “happy hypoxic”)

b. Type H - characterized by high elastance, low compliance, high lung weight, high lung recruitability, and high right-to-left shunt. This type of pneumonia has features similar to typical ARDS.

Possible Pathogenesis and Treatment Strategy

Clinical studies on pathogenesis of COVID-19 shows association with coagulopathy. This however differs from sepsis-associated disseminated intravascular coagulation (DIC) by the relatively normal levels of PT, fibrinogen, and platelets, despite markedly elevated d-dimer levels. Although the primary pathogenesis was thought as pulmonary type II pneumocyte injury, viral pneumonia, ARDS or macrophage activating like syndrome complicating ARDS leading to DIC; the pathological evidence from autopsy series show that the major pathogenic mechanism is “Pulmonary Intravascular Coagulopathy (PIC)” as firstly named by McGonagle et al. This is a kind of immune thrombosis that is distinct from classical DIC.

SARS-CoV2 binds to Angiotensin Converting Enzyme 2 (ACE2) receptors on type II pneumocytes and possibly on vascular endothelial cells and causes lysis of the cells immediately leading to direct activation of the endothelium causing procoagulant activity and activates accumulation of fibrin deposits in pulmonary microcapillary venous vessels. The fibrin deposits cause a compensatory mechanism of increased plasminogen at the beginning but as the disease progresses fail to break down the fibrin deposits reflected in increased d-dimer levels.

In the lung, SARS-CoV-2 causes acute diffuse alveolar damage, pneumocyte hyperplasia, and interstitial pneumonia.

In the acute stage of ARDS, there is diffuse alveolar damage in the lung along with formation of hyaline membrane in the alveoli which is followed sequentially by interstitial widening edema and later proliferation of fibroblasts in the organizing
stage. COVID-19 ARDS causes the typical ARDS pathological changes of diffuse alveolar damage in the lung. During the illness, lung fibrosis appears in the long term.

Coagulation dysfunction is common in COVID-19 (detected by raised D-dimer levels). Fatal cases have shown diffuse microvascular thrombosis, suggesting a thrombotic microangiopathy, and evidence of thrombotic DIC. This explains the atypical manifestations seen in the lung, like dilated pulmonary vessels on the CT Chest, and episodes of pleuritic pain. Vascular enlargement is not seen in typical ARDS, but seen in most cases of COVID-19 ARDS.

Microscopy: Microscopic picture shows exudative and proliferative phases of diffuse alveolar damage. Electron microscopy reveals that viral particles were predominantly located in the pneumocytes. The predominant pattern of lung lesions in patients with COVID-19 is diffuse alveolar damage, as described in patients infected with SARS and MERS coronaviruses. Hyaline membrane formation and pneumocyte atypical hyperplasia are frequent. The presence of platelet–fibrin thrombi in small arterial vessels is consistent with coagulopathy, which appears to be common in patients with COVID-19 and should be one of the main targets of therapy.

Biomarkers: Recent studies have suggested that in addition to direct viral damage, uncontrolled inflammation contributes to disease severity in COVID-19. Consistent with this hypothesis, high levels of inflammatory markers, including C-Reactive protein (CRP), ferritin, D-dimer, high neutrophil-to-lymphocyte ratio, increased levels of inflammatory cytokines and chemokines have been observed in patients with severe disease. Pathogenic inflammation, also referred to as cytokine storm, shares similarities with SARS-CoV and MERS-CoV. Inflammatory cytokines IL-6, IL-8, TNF-α, and IL-1β could help predict the course and outcome of disease in COVID-19. A high IL-6 predicted a 227% increase in chances of death, and TNF-α reduced the chances of survival by 150%. It has been found that when IL-6 and TNF-α are high at the time of admission, the patient is likely to have severe disease and reduced survival, irrespective of the use of other clinical and laboratory findings.

Procalcitonin (PCT) has emerged as a crucial biomarker for the severity and prognosis of COVID-19 infection. Italian researchers have reported that the risk of severe SARS-CoV-2 infection was nearly five times higher in COVID-19 patients with raised PCT levels. A retrospective, multi-center study of 191 confirmed COVID-19 cases in Wuhan, China, reported that three indicators—higher Sequential Organ Failure Assessment (SOFA) score, a D-dimer ≥1 µg/L, and advanced age—produced significantly higher mortality risk. These markers could help identify patients in the early stages of COVID-19 with a poor prognosis.

Laboratory: The protocol for doing a RT-PCR is as per Table 1. Peripheral white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), derived NLR ratio [(d-NLR), neutrophil count divided by the result of WBC count minus neutrophil count], platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are indicators of the systematic inflammatory response that are widely investigated as useful predictors for the prognosis of viral pneumonia. WBC count, NLR, LMR, PLR, CRP, and d-NLR of severe patients were significantly higher than those of non-severe patients. The optimal threshold at 3.3 for NLR showed a superior prognostic possibility of clinical symptoms to change from mild to severe, which had the highest of sensitivity and specificity. When age ≥49.5 years and NLR ≥3.3, 46.1% of the COVID-19 patients with mild disease became severe in a mean time of 6.3 days. Therefore, these patients must be closely attended to by clinicians. By contrast, when age <49.5 years and NLR <3.3, COVID-19 patients with mild disease were cured and discharged in approximately 13.5 days.

The Systemic Inflammation Index (SII = neutrophil × platelet-to-lymphocyte ratio), the aggregate index of systemic inflammation (AISI = neutrophil × platelet × monocyte-to-lymphocyte ratio), and systemic inflammation response index (SIRI = neutrophil × monocyte-to-lymphocyte ratio), are all used as markers to predict mortality in COVID-19 patients admitted to hospital. However, SII emerged as the sole reliable COVID-19 prognostic hematological parameter in the retrospective evaluation of COVID-19 patients.

## Determinants of Adverse Outcomes

COVID-19 ARDS appears to have significantly worse outcomes compared to ARDS from other causes, as per Table 2.
Risk factors for poor outcomes include advanced age; presence of comorbidities such as hypertension, cardiovascular disease, and diabetes mellitus; lower lymphocyte counts; kidney injury; and raised D-dimer levels. Patients with pulmonary arterial hypertension (PAH) often fare worse compared to patients with other conditions.

Radiodiagnosis and Imaging in COVID19 ARDS

Imaging assists in establishing diagnosis; triage; and providing management guiding actionable results. The radiological armamentarium available for COVID includes routine chest radiograph (CXR), CT, and point-of-care thoracic ultrasonography (POCUS).

CXR is sensitive only when patients present late or with advanced symptoms. CXR findings include patchy peripheral consolidation or ground glass opacities (GGO) with predilection for lower and middle lobes. The consolidation is bilateral in 75% of patients and unilateral in 25%. Occasional nodules, perihilar consolidation, and prominence of perihilar vasculature are also noted.

Non-contrast high-resolution continuous helical CT scan of the thorax is the preferred protocol for evaluating COVID-19 patients. However, contrast may be administered in select cases to exclude other complications like pulmonary thromboembolism. GGO with peripheral and lower lobe predilection are the most common findings. In addition, crazy paving (GGO with thickened interlobular and intralobular septa), vascular distension in region of GGO may be seen early in the disease. Later, the imaging appearance progresses to architectural distortion, subpleural bands, fibrosis, and traction bronchiectasis. Consolidation may superimpose on the GGO later in the disease and in older and high-risk individuals. Pleural effusion, pericardial effusion, lymphadenopathy, and pneumothorax are also uncommonly seen.

COVID-19 can initially present as a subpleural disease. Therefore, the accuracy of POCUS as screening tool is limited. It has significant value, however, in monitoring the progress of critically COVID patients in ICU. The findings are described with images in Table 3.
Alongside the subclinical ventricular relaxation impairment (given the advanced age and comorbidities like systemic hypertension), the conglomeration of factors specific to COVID-19 such as systemic inflammatory milieu, endothelial dysfunction, microvascular thrombosis, arrhythmias, disturbed ventricular cross-talk (owing to the concomitant right ventricular dysfunction resulting from pulmonary hypertension), and myocardial oxygen supply-demand perturbations, can contribute significantly to the LVDD with a subsequent accentuated potential to culminate as heart failure with preserved ejection-fraction (HFpEF).

At the same time, the use of high positive end-expiratory pressure (PEEP), quite commonly employed while ventilating hypoxemic COVID-19 patients can also result in an attenuated cardiac output in the face of an already impaired ventricular filling in HFpEF.

Among patients developing clinical deterioration during follow-up (20% of hospitalized patients), repeat echocardiogram shows further deterioration of the right ventricular parameters, probably related to increased pulmonary resistance.

The underlying cardiopulmonary interactions present unique challenges in weaning the mechanically ventilated patients with co-existent LVDD.

Medical Management of SARS CoV-2 Infection

In view of the lack of availability of approved specific drug therapy for SARS CoV-2 treatment is essentially supportive and symptomatic. The initial step involves triage of patients of SARS CoV-2 into mild, moderate, severe, and critical categories depending upon the severity of clinical presentation vide WHO and CCDC guidelines.[24]

Patients with worsening hypoxia require management in hospital with supplemental oxygen by either high flow nasal cannula (HFNC) or non-invasive ventilation. Intubation and mechanical ventilation are indicated in patients having severe illness. They may also require concomitant intensive care management of multiorgan dysfunction by a multidisciplinary team of treating specialists. The treatment of severe COVID-19 illness includes aggressive treatment of complications, prophylaxis for secondary infection, thrombotic events, and organ function support based on treatment of underlying disease.[25] ICU practices that prevent ARDS or aid in early recognition and effective treatment of the events leading to ARDS, like lung-protective ventilation and conservative fluid management, remain essential elements to achieve desired improved outcomes.
As there is no approved specific pharmacotherapy for COVID-19, various drugs have been tried by treating doctors across the world with variable results. Currently, research trials are underway to find a definite cure, but there is no consensus on a specific drug being effective in curing SARS-CoV-2 infection. Experimental and repurposed therapies that stand unsupported by strong evidence are to be strongly discouraged.

**Treatments Evaluated for COVID-19**

(a) Hydroxychloroquine: Based on experience with earlier viral illnesses, HCQ was proposed to be likely effective therapy for COVID-19 besides prophylaxis. In an observational study by Joshua et al. involving 1,376 patients with COVID-19 admitted to the hospital, HCQ administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. It has now been stopped because of lack of efficacy. WHO guidelines recommend against prescribing HCQ for prophylaxis (both post and pre-exposure) in individuals with confirmed or suspected exposure to SARS-CoV-2.

(b) Hydroxychloroquine plus Azithromycin: Combination therapy was initially attempted to treat COVID-19, however, subsequently discontinued because of cardiac arrhythmias secondary to increased QT interval resulting in fatality in a few.

(c) Lopinavir-Ritonavir: These anti-retroviral drugs, initially considered promising in SARS-CoV-2 infection failed in expected outcomes. WHO accepted the recommendation from Solidarity Trial’s International Steering Committee vide press release dated 04 July 2020 to discontinue lopinavir-ritonavir arm of the trial because of evidence of little or no reduction in mortality of hospitalized COVID-19 patients when compared to standard of care.

(d) Favipiravir: This selective RNA polymerase inhibitor, under study in various trials around the world, inhibits viral replication. Two clinical trials (Japan, USA) and a phase-3 clinical trial in India using favipiravir combined with another antiviral agent, Umifenovir are ongoing. Results are awaited.

(e) Remdesivir: A nucleotide analogue produg that is intracellularly metabolized to an analogue of adenosine triphosphate that inhibits viral RNA polymerases has shown in vitro activity against SARS-CoV-2. The first published report with a group of patients receiving remdesivir in a compassionate-use programme, described clinical improvement in 36 of 53 hospitalized patients (68%) with severe COVID-19. US FDA issued an EUA of remdesivir to allow its emergency use for severe

| Table 4: Summary of drugs evaluated for COVID-19 |
|-----------------------------------------------|
| **Drugs** | **Indications** | **Doses** | **Special Considerations** |
|----------------|----------------|-----------|---------------------------|
| Hydroxychloroquine | COVID-19 (moderate/severe/critical) | 400 mg BD on day 1, then 200 mg BD x next 4 days | Due to its propensity to develop QT prolongation and cardiac arrhythmias now it is not recommended. Also has risk of fetal ocular toxicity. |
| HCQ plus Azithromycin | COVID-19 (moderate/severe/critical) | HCQ dose as above, Azithromycin 500 mg OD on D1, then 250 mg OD x 4 days | Obtain baseline EKG preferably not during sinus tachycardia (if QTc >500 msec then avoid giving this drug combination due to risk of cardiac arrhythmias). Currently not recommended for use due to poor risk-benefit ratio. |
| Lopinavir-Ritonavir | Severe to critical COVID-19 illness | Lopinavir 400 mg + Ritonavir 100 mg BD upto 10 days | In hospitalized patients no benefit observed beyond standard care. Cause QT prolongation and ALT elevation |
| Favipiravir | COVID-19 (mild to moderate illness) | Loading dose of 1800 mg BD on day 1, followed by a maintenance dose of 800 mg BD from day 2 to maximum of day 14. | Recommended in COVID-19 management protocols for use in some countries. Early trends of various trials have shown better viral clearance among patients started early on treatment with it, however, more trials needed to assess its clinical efficacy in COVID-19. |
| Remdesivir | Severe to critical COVID-19 illness | 200 mg IV on day 1, followed by 100 mg IV OD x 9 days | Currently suspended by WHO for routine use for most patients outside clinical trials except for emergency use in pregnant patients and children. Monitor hepatic transaminases. |
| Tocilizumab | Critical COVID-19 cases on already optimized treatment who meet criteria for cytokine storm | 400 mg IV once | To be considered on case to case basis only. Exclusion criteria: Age >70 years, ILD, pancreatitis, AST/ALT >5 x ULN, CHF with EF<30%, Neutrophils <500 cells/cumm, platelet count 50000/cumm, myoglobin >100 ng/mL, sepsis due to other pathogens, poor prognosis (unlikely to survive >48 h) |
| Dexamethasone | Severe/critical COVID-19 | 6-8 mg PO/IV daily for upto 10 days or discharge whichever is early | RECOVERY trial showed systemic steroids reduce 28-day mortality & systemic inflammatory response leading to lung injury & MODS in hospitalized patients with COVID-19 patients who required supplemental oxygen with maximum benefit in those requiring mechanical ventilation. No survival benefit seen in those not requiring oxygen supplementation. |
COVID-19 (confirmed or suspected) in hospitalized patients.\textsuperscript{[28,29]} Currently, several phase-3 clinical trials are evaluating it for treatment of moderate and severe COVID-19.

(f) Dexamethasone: Practise of using dexamethasone varied widely across the world with many treatment guidelines having conflicting reports on use of corticosteroids in COVID-19 illness\textsuperscript{[30]} but in China they were being used in severe cases.\textsuperscript{[31]} However, the RECOVERY trial (with over 11,500 patients enrolled from over 175 NHS hospitals in the UK) provided clear evidence that dexamethasone 6 mg per day for up to 10 days reduces 28-day mortality in COVID-19 patients receiving invasive mechanical ventilation by one-third, and by one-fifth in patients receiving oxygen without invasive mechanical ventilation. No benefit was demonstrated in hospitalized COVID-19 patients who were not receiving respiratory support and results were consistent with possible harm in this group.\textsuperscript{[32]}

(g) Convalescent Plasma: Convalescent plasma, collected from donors having recovered from recent COVID-19 infection, contains anti-SARS-CoV-2 virus antibodies that can be used to treat other COVID-19 patients. Data from a study in USA involving 20,000 patients transfused with COVID-19 convalescent plasma demonstrate that its use is safe and carries no excess risk of complications and supports the premise that administration of the same early during illness is likely to reduce mortality.\textsuperscript{[33]} Another study by Liu et al. showed that convalescent plasma transfusion improved survival in non-intubated patients but not in intubated patients.\textsuperscript{[34]} The FDA states that it is important to determine its safety and efficacy via clinical trials before routinely administering convalescent plasma to patients with COVID-19.

(h) Interleukin-6 (IL-6) inhibitors: Interleukin-6 is a pleiotropic pro-inflammatory cytokine produced by various cell types including lymphocytes, monocytes, and fibroblasts. SARS CoV-2 virus induces IL-6 production from bronchial epithelial cells causing inflammation. Various IL-6 inhibitors (like sarilumab, tocilizumab) are under evaluation for their efficacy in management of COVID-19. However, presently there is inconclusive data to recommend for or against the use of IL-6 inhibitors.\textsuperscript{[35]}

(i) Nitric Oxide: Potential role of inhaled nitric oxide (iNO) in preventing progression of disease in those with severe ARDS is under evaluation.\textsuperscript{[36]} Routine use of iNO in patients with COVID-19 pneumonia is not recommended and the trial is recommended only in mechanically ventilated patients with severe ARDS and hypoxemia despite other rescue strategies.\textsuperscript{[37]} Studies are ongoing to evaluate for the efficacy and safety of iNO in SARS-CoV-2 patients requiring supplemental oxygen before the disease progresses to necessitating mechanical ventilatory support.

(k) Anticoagulants: To break fibrin deposits in pulmonary microvasculature, the treatment strategy is focussed at blockage of hypercoagulation with low-molecular weight heparin (LMWH) for blocking thrombin and dampen the inflammatory response. LMWH at prophylactic doses should be administered to all symptomatic patients with microbiologically or radiologically documented COVID-19 diagnosis and escalated to therapeutic doses in case of respiratory distress. In case LMWH is insufficient of preventing further activation of PIC and the thromboses extend to pulmonary veins, the process will proceed to secondary pulmonary hypertension and cardiac insufficiency. Increased intravascular pressure in lungs will result in extensive alveolar exudation, resulting causing marked hypoxia. As a consequence of decreased pulmonary venous flow, the left ventricular stroke volume will decrease leading to systemic hypotension. The treatment option at this step should be Tissue Plasminogen Activator (TPA) or defibrotide. These two fibrinolytic modalities can prevent intubation and progression to DIC.

(l) COVID-19 Vaccine: As of 18 February 2021, at least seven different vaccines across three platforms have been rolled out in countries. Vulnerable populations in all countries are the highest priority for vaccination. The vaccines must be proven safe and effective in large (phase III) clinical trials. Some COVID-19 vaccine candidates have completed their phase III trials, and many other potential vaccines are being developed. An external panel of experts convened by WHO, called the Strategic Advisory Group of Experts on Immunization (SAGE), analyses the results from clinical trials, along with evidence on the disease, age groups affected, risk factors for disease, programmatic use, and other information. SAGE then recommends whether and how the vaccines should be used.

The vaccines available for use in the USA, and India are displayed in Tables 6 and 7.

In India, on April 12, 2021, Russian Sputnik V COVID-19 vaccine was approved for use.

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process as on June 03rd is attached as Appendix 1.\textsuperscript{[38]}

While a COVID-19 vaccine will protect you from serious illness and death, we still don’t know the extent to which
it keeps you from being infected and passing the virus on to others. To help keep others safe, COVID appropriate behaviour is necessary. Always follow guidance from local authorities based on the situation and risk where you live.

**Oxygenation and Ventilation for COVID-19 ARDS Patients**

COVID-19 ARDS follows an anticipated time course, with a median time to intubation of 8–10 days after symptom onset.\[39\] It is therefore imperative to constantly monitor patients for the development of ARDS as the days of infection progresses. The primary strategy for COVID-19 patients is supportive care, which includes oxygen therapy for hypoxemic patients. Oxygen therapy is instituted if respiratory rate is of 30 breaths/min. or above and/or SpO2 of 93% on breathing air.

**NON-INVASIVE MODES**

High-flow oxygen therapy (HFNO) should be started if there is a respiratory failure and mild–moderate ARDS. HFNO is used as first-line treatment, followed by noninvasive ventilation (NIV) in CARDS.\[39\] However, NIV is not recommended for patients with failed HFNO. NIV provides benefit via PEEP, to patients with mild–moderate ARDS by reducing the respiratory load and intubation rate but it can cause significant aerosol generation.

High-flow nasal cannula (HFNC) for HFNO is effective in improving oxygenation, but due to reports of high amount of aerosol dispersion it was not recommended initially. However, further studies in patients with acute hypoxemic respiratory failure, HFNC was proven to avoid intubation compared to conventional oxygen devices, and the scientific evidence of generation and dispersion of bio-aerosols via HFNC showed a similar risk to standard oxygen masks. HFNC prong with a surgical mask on the patient’s face is thus a reasonable modality to benefit hypoxemic COVID-19 patients and avoid intubation.\[40\]

**INTUBATION AND INVASIVE MECHANICAL VENTILATION OF COVID-19 ARDS PATIENTS**

Mechanical ventilation of COVID-19 patients with ARDS is really a challenging task as these patients usually have non-homogenous lung pathology. This requires a targeted lung-protective ventilation strategy to improve the outcome.

The indications for mechanical ventilation for COVID-19 ARDS\[41,42\] are as follows:
1. Acute hypoxic respiratory failure with severe respiratory distress.
2. Worsening hypoxia associated with increased labored breathing.
3. Increased work of breathing associated with use of accessory muscles of respiration.
4. Failure to maintain SpO₂ >90% with >50 L/min of HFNO or with maximal supplemental oxygen.
5. Hypoxia with altered mental status and failure to maintain airway patency.
6. Patient with multiorgan failure, persistent hemodynamic instability requiring vasopressor support, or those with multiple comorbidities like (DM, Cardiovascular disease, hypertension, advanced age, frailty, cancer, or chronic respiratory disease).
7. Arterial pH <7.3 with PaCO₂ >50 mm Hg.
8. PaO₂/FiO₂ <200.[43]
9. High respiratory rate with persistent thoraco-abdominal asynchrony or paradoxical respiration.
10. Low ROX index[44] (<4.88) with patient on HFNC.

The indications for intubation and mechanical ventilation in COVID-19 patients are not limited to the above-mentioned conditions and are at the discretion of the treating physician.[45]

Precautions and Procedures while intubating COVID-19 patients

Airway management and intubation in COVID-19 patients is an aerosol-generating procedure and is associated with increased risk of viral transmission to the healthcare providers. Hence, a high level of attentiveness and alertness is necessary to prevent infection when intubation is performed. The following points are to be ensured for safety of patients and healthcare providers[46].
1. Standard level 3 protection should be donned while performing intubation.
2. Standard monitoring, IV access, instruments, drugs, ventilator, and suction should be pre-checked.
3. Tracheal intubation should be performed by the most experienced anesthesiologist in an airborne infection isolation room to ensure patient safety as well as of healthcare worker (HCW)
4. Limit the number of healthcare providers in the room/cubicle prior to intubation.
5. Use 3–5 min. pre-oxygenation with 100% oxygen as these critical patients have poor oxygen reserve.
6. Spontaneous ventilation should be preserved and assisted bag mask ventilation during preoxygenation should be avoided.
7. RSI (rapid sequence intubation) technique should be used to avoid manual ventilation of the patient’s lungs and the potential aerosolization of the virus from the airways.[47]
8. Use both hands to hold the mask to ensure a tight seal using the V-E technique rather than the C-E technique with one hand.
9. Video laryngoscope is preferred for intubation.
10. Airway management should be safe, accurate, and should be accomplished within 15–20 s.
11. After tracheal intubation, clamp the endotracheal tube (ETT) and inflate the cuff before instituting ventilation. A COVID aerosol barrier has been used extensively for intubation.[48]
12. Viral and HME filter to be applied between endotracheal tube and circuit.
13. Proper tube placement can be identified by EtCO₂ monitoring and visible bilateral chest rise. Avoid auscultation to confirm tube placement.
14. Supraglottic airway devices (SGAD) to be used in CICO (Can’t intubate and can’t oxygenate) situations only and bedside tracheostomy to be performed as early as possible.

Ventilatory strategy for COVID-19 ARDS

The most appropriate time to intubate COVID-19 patients is still not clear. However, early and timely institution of mechanical ventilation can be considered if the COVID-19 patient develops moderate to severe ARDS (PaO₂/FiO₂ <200) to prevent Patient self-induced lung injury (P-SILI).[43] Non-intubated spontaneously breathing ARDS patients are at increased risk of P-SILI because of high intake of inhaled tidal volume. Therefore, esophageal pressure measurement by manometer can be considered in spontaneously breathing, non-intubated patients to decide the time for intubation.[49] The esophageal pressure between 05 and 10 cm H₂O is usually well tolerated. However, if pressure progresses beyond 15 cm H₂O, then the risk of P-SILI increases and intubation shouldn’t be delayed. If esophageal manometry is not available, then change in CVP (central venous pressure) with respiration or clinical assessment of excessive inspiratory effort for increased work of breathing can be considered [Figure 3].[50]

Mortality is very high for COVID-19 ARDS patients on mechanical ventilation. Inappropriate ventilatory strategy in ARDS patients can lead to Ventilator induced lung injury (VILI), which includes barotrauma (high airway pressure), volutrauma, atelectrauma, biotrauma, myotrauma (diaphragmatic injury), and oxytrauma (oxygen free radicals).

Strategies to promote lung protection in ARDS: -
- a. **Lung protective ventilation**[51].

This approach of ventilation in patients with ARDS is based upon several randomized trials and meta-analyses that have reported survival benefit from lung-protective
ventilation. Initial ventilatory settings for these patients are recommended as below:

b. Role of PEEP in COVID-19 ARDS
There is an ambiguity with respect to the usage of adequate PEEP for COVID-19 ARDS patients. Using higher PEEP (any PEEP >10 cm H₂O) was not recommended based on the heterogeneity of lung involvement in COVID-19 patients with simultaneous existence of severely affected areas with non-affected areas in the lung. However, surviving sepsis campaign guidelines on management of critically ill adults from COVID-19, European Intensive and Critical Care Guidelines, recommend PEEP >10 cm H₂O for management of ARDS because of SARS-CoV-2.

c. Compliance
In COVID-19 patients, lung compliance needs to be constantly assessed. If compliance is high or normal with the existence of hypoxemia, it is recommended to use a PEEP of less than 10 cm H₂O to avoid over-distention of normal healthy alveoli. However, if compliance is low as seen in ARDS, then it’s advised to use adequate PEEP of just above the lower inflection point on the pressure volume loop on the ventilator to recruit collapsed alveoli, to prevent atelectasis, and thereby improve oxygenation. Once the initial setting on the ventilator is entered, monitoring of the following parameters is done to ascertain patient progress:

1. Plateau pressure – Pplat should be below 30 cm H₂O.
2. Driving pressure is kept below 15 cm H₂O. This can be achieved by either decreasing tidal volume (at the risk of development of hypercapnia) or by increasing PEEP, which can cause over-distention of alveoli. Therefore, careful titrations are required.
3. Compliance – Normally the total compliance of both lungs in an adult is about 200 ml/cm H₂O. Low compliance is usually found in ARDS patients with stiff lung. There are two types of lung compliance:
   a. Static compliance = Tidal volume/(Pplat - PEEP)
      Static compliance measures pulmonary compliance when no airflow such as during inspiratory pause and it is slightly higher than dynamic compliance.
   b. Dynamic compliance = Tidal volume/(PIP – PEEP)
      It represents pulmonary compliance during active inspiration and depends upon peak inspiratory pressure (PIP). PIP depends on airway resistance. COVID-19 pneumonia usually has high compliance (>40 ml/cm H₂O). Therefore, management should be instituted with low PEEP and high tidal volume up to 8–9 ml/kg, if hypercapnia presents.

4. Airway occlusion pressure (PO.1) – The normal value of PO.1 in a spontaneously breathing patient is about 1 cm H₂O. However, in mechanically ventilated patients, values above 3.5 cm H₂O are associated with increased effort. Keep airway occlusion pressure value in COVID-19 ARDS patients less than 3.5 cm H₂O to obtain a ventilatory strategy protective for the lung to prevent it from VILI and diaphragmatic injury (Myotrauma).

d) Target goals of mechanical ventilation
• Target SpO₂ = 90-94%
• PaO₂ >55 mm Hg.
• pH >7.2
• Fio2 <0.4
• PaO₂/FiO₂ >300 mm Hg.

Subsequent ventilatory setting can be decided by periodic checking of Pplat pressure, driving pressure, compliance, and ABG (pH, Oxygenation level). If Pplat pressure >30 cm H₂O, then tidal volume can be decreased to 5 ml/kg or if required, further decreases then tidal volume set to 4 ml/kg of predicted body weight.

e) Adjunctive therapy: The use of adjunctive treatment is relatively less during initial presentation in patients with ARDS, but gradually increase with ARDS severity.
• Sedation
A combination of multiple agents like (propofol, ketamine, fentanyl, morphine, hydromorphone, dexmedetomidine, and midazolam) may be considered for sedation of COVID-19 patients on mechanical ventilator. Usually, COVID-19 patients require high level sedation to ensure patient comfort, alleviate pain, anxiety, avoid ventilator asynchrony, and self-extubation.
• NMBA (neuromuscular blocker agents)
Can be used in boluses in patients with refractory hypoxemia or ventilator asynchrony to facilitate protective and improved lung ventilation. It also causes reduction of high pulmonary inflation pressures (e.g., ARDS), raised intracranial pressure, and metabolic rate (e.g., work of breathing, shivering).
• Recruitment maneuvers
WHO interim guidelines recommend the use of intermittent recruitment maneuvers with high PEEP to improve oxygenation in ARDS. However, there are contradicting reports on the use of the same.
• Steroid administration
WHO recommends steroid administration in COVID-19 ARDS patient on mechanical ventilator if
they develop septic shock and require increasing dose of vasopressor to maintain MAP >65 mm Hg in a dose of Inj. Hydrocortisone - 200 mg/day or Prednisolone 75 mg/day.

- Fluid therapy
  Conservative or restricted fluid therapy over liberal fluid is advised, as it may worsen oxygenation in mechanically ventilated ARDS patients.

- Management of septic shock
  WHO interim guidelines recommend the use of crystalloid intravenous balanced fluids like normal saline, Ringer’s lactate as fluid bolus (01 litre over 30 min. or faster) for septic shock to check for fluid responsiveness; and avoid using hypotonic fluids, starch-based solution for resuscitation. If no fluid response occurs OR signs of fluid overload appear like crackles on auscultation, then discontinue the fluid and consider using vasopressors. In vasopressors, norepinephrine is the drug of choice, followed by vasopressin and dobutamine to maintain MAP >65 mm Hg and preferably be given through central venous line. These vasopressors to be given as per strictly controlled rate decided as per targeted blood pressure to maintain tissue perfusion. However, peripheral lines can be considered in resource-limited settings keeping a close watch for necrosis of skin or extravasation of vasopressors.

(f) Prone ventilation
  If lung-protective ventilation fails to maintain adequate oxygenation and if PaO2/FiO2 <150 mm Hg with PEEP >5 and FiO2 >0.6, then prone ventilation should be considered. Prone ventilation improves oxygenation and decreases V/Q mismatch, particularly when applied early with other lung-protective strategies. In COVID-19 patients, good response to prone positioning may be because of their well-preserved lung compliance compared to patients who develop ARDS from other causes. By optimizing patient selection and treatment protocols, the recently Proning Severe ARDS Patients (PROSEVA) trial demonstrated a significant mortality benefit with prone ventilation.

(g) Role of pulmonary vasodilators
  The two most commonly used vasodilators in mechanically ventilated patients are inhaled nitric oxide gas (NO) and epoprostenol, and this remains a concern in COVID-19 patients. That is why inhaled NO is preferred over epoprostenol. In COVID-19 ARDS patients, there is yet no conclusive evidence on the use of pulmonary vasodilators.

(h) Role of ECMO
  Even after prone ventilation, if oxygenation doesn’t improve and hypoxia still persists, then veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be considered. Its use as rescue therapy is considered only in refractory hypoxic respiratory failure. No RCTs or meta-analyses have been conducted for ECMO in COVID-19 patients with ARDS, however, there are reports from China stating its beneficial use. But the process and outcomes have not been mentioned.

(j) Ventilator Weaning and Extubation
  Special focus needs to be ensured to avoid viral transmission to the healthcare providers during extubation as it is also an aerosol-generating procedure. Since there is a high chance for reintubation in many patients, some physicians like to use cuff leak test criteria along with spontaneous breathing trials (SBT). This is done to assess the readiness for weaning from mechanical ventilation on the assumption that these patients could have developed airway oedema due to prolonged ventilation. Aerosol generation in cuff leak test is similar to extubation, so caution needs to be taken while performing a cuff leak test. SBT without T-piece at lower pressure support (0-3 cm H₂O) and along with prior use of steroid to extubation yielded promising results. The following weaning criteria is recommended before extubation:
  1. Patient should be conscious, comfortable, and oriented.
  2. PaO2/FiO2 >300 mm Hg with PEEP <5 cm H₂O.
  3. Hemodynamically stable and maintaining SpO2 with FiO2 <0.4.
  4. RSBI (Rapid shallow breathing index <105) – calculated by respiratory rate/tidal volume in liters when the intubated patient is breathing spontaneously.
  5. No signs of increased work of breathing or respiratory distress like use of accessory muscles, paradoxical or asynchronous respiration, nasal flaring, profuse diaphoresis, agitation, tachypnoea, tachycardia and cyanosis.

(j) Prevention of complications
  1. The prevention of complications associated with mechanical ventilation in COVID-19 patients is important and should be implemented (Table…….). The following can be incorporated. In a table. Prevention of VAP.
2. Reduce pressure sores and ulcers by frequent change of position every 2 hours.
3. Reduce stress ulcer, gastric bleeding by early enteral feeding, and consider PPI or H2 blocker.
4. Reduce ICU related weakness by early mobilization.
5. Reduce urinary catheter related infection by using sterile aseptic technique while insertion and consider removal when not needed.
6. Reduce the number of days on mechanical ventilation by daily assessment for readiness of extubation through spontaneous breathing trials.
7. Reduce the incidence of venous thromboembolism by use of pharmacological agents or mechanical compression devices.

Neuropsychiatric Symptoms in COVID-19

Long-term outcomes of patients with ARDS are being increasingly recognized as important research targets, as many patients survive ARDS only to have ongoing functional and/or psychological sequelae.

Neuropsychiatric symptoms are atypical presentations of COVID-19. There is a myriad of symptoms ranging from mild headache and myalgia in majority of cases to life threatening seizures and delirium in patients with severe respiratory compromise (ARDS), especially in patients with underlying comorbidities.

Neuropsychiatric symptoms are estimated to appear in around 30% of COVID-19 infected patients. Moderate to severe infection can impair executive functions, confusion, and agitation.

The neurological complications can be divided into primary neuroinvasion by the coronavirus or secondary wave by activated immune and inflammatory mediators. The virus enters the nervous system either directly from the olfactory nerves pathway or is spread via hematogenous route and attaches onto the ACE-2 receptors on the neuronal endothelium. This acute involvement can cause meningitis/encephalitis leading to altered sensorium, delirium, seizures, and/or even coma. It is also hypothesized that direct invasion of medullary neurons could be responsible for severe respiratory failure. Alterations in sensorium and delirium could also be because of hypoxia from respiratory failure, aberrations in coagulation pathways, metabolic imbalances, multiorgan dysfunction, or even iatrogenic (drugs used during mechanical ventilation). Long-term sequelae could be attributed to alterations in immune response and consequent aberrant inflammatory response.

Delirium- The prevalence of delirium in intubated patients is up to 80%, which expectedly upswings in a COVID-19 patient with ARDS.

The risk factors include old age (>65 years), medical comorbidity, drugs (propofol, opioids, and high-dose benzodiazepines, which are routinely used during mechanical ventilation, and hydroxychloroquine). There are certain COVID-specific environmental risk factors such as mandatory wearing of personal protective equipment (PPE) which accentuates the anxiety and feeling of vulnerability in an alien environment. The patient is deprived of the reassuring and empathetic look on the doctor’s face. All these risk factors can impair the patient’s perception of the reality and cause disorientation and confusion.

Scales for assessment of Delirium:

The time-tested Confusion Assessment Method for the ICU should be followed routinely. Other useful scales are Intensive Care Delirium Screening Checklist and the Stanford Proxy Test for Delirium.

Management

A) Non pharmacologic:
1. Ensuring a comfortable ambient light in sync with the diurnal cycle.
2. Ensuring a pain-free spell of 6–8 h of sleep without significant treatment related disruptions.
3. Regular cognitive stimulation and reorientation of the patient to time, place, and person (utilizing AV aids for virtual communication with family members/other familiar people).
4. Encouraging physical mobilization at the earliest.
5. Providing all kinds of possible aids (glasses, hearing aids, mobiles, etc.) to convey a feeling of self-sufficiency and sense of control over the situation.

B) Pharmacologic
1. Sleep cycle:
Melatonin should be used for regularizing sleep–wake cycle in delirium as it has a short half-life, has additional mild anti-inflammatory properties, and does not cause respiratory depression. Suvorexant (Orexin antagonist) has also been used especially in conjunction with Melatonin. Benzodiazepines should be avoided (except in cases of delirium tremens), as cumulative doses run the risk of respiratory depression and may cause paradoxical disinhibition. Zolpidem (2.5–5 mg) is relatively safer in terms of respiratory functioning, but levels are increased in patients taking ritonavir.
2. Acute agitation/Disruptive behavior
Antipsychotic drugs like haloperidol, olanzapine, or quetiapine are found to be beneficial in the management of the agitation. However, monitoring of QTc interval, neurologic side effects (EPS), and sedation are required. The risk of QTc prolongation gets further amplified, given the potential use of COVID-19-specific medications that themselves prolong QTc (hydroxychloroquine, azithromycin), leading to a potentially increased risk of torsades de pointes.\(^{[75]}\)

a) Haloperidol being a potent dopamine receptor blocker with insignificant anticholinergic and antihistaminic activity (2.5–5 mg) can be used orally or intramuscularly. Intravenous administration should be accompanied by ECG monitoring. Recent research has also shown that haloperidol, due to its effects on sigma receptors, is investigated as a treatment for COVID-19.\(^{[76,77]}\)

b) Olanzapine 5–10 mg can also be considered either orally or parenterally. In acutely disturbed patients, intramuscular (IM) is the preferred route of administration compared to intravenous (IV) route and gluteal IM injections may be preferred over deltoid injections to increase the distance between respiratory secretion/droplet. IM olanzapine has minimal effect on QTc interval and lesser risk for EPS compared to haloperidol.

c) Quetiapine (25–50 mg) can be given orally.

d) Dexmedetomidine is alpha-2 agonist and reduces the release of noradrenaline and helps curtailing restlessness. Clonidine can also be used for the same reason and is more convenient as its available in skin patches form.

e) Valproic acid is known for its neuroprotective\(^{[78]}\) potential and can be used to control extreme emotional fluctuations. It also provides prophylaxis against the potentially epileptogenic state by increasing the seizure threshold. However, liver function tests and platelets need to be constantly monitored.

f) In extreme cases not responding to the above measures, only short acting low dose oral benzodiazepines (e.g., lorazepam 1–2 mg) may be considered with close monitoring for respiratory distress and respiratory failure.

g) Mechanical restraint: Mechanical restraint should be used as a last resort for minimum possible time.

3. Mechanical Ventilation

Weaning off mechanical ventilation at times can be associated with acute and severe anxiety that could result in delay in extubation. A very low dose of antipsychotic- Tab Olanzapine 2.5 mg is advisable for anxiolysis.

Drug treatment of patients with pre-existing psychiatric illness

Most psychiatric illnesses are remitting and relapsing in nature and generally require long-term prophylaxis. In the absence of a confirmed treatment for management of COVID-19, a multitude of pharmacotherapeutic agents have been tried in the recent past and can have significant drug interactions with psychotropics and can precipitate a relapse of the illness. Hence, it is imperative to be mindful of such interactions.

I. Antipsychotics

Haloperidol, quetiapine, ziprasidone, etc., can prolong QTc interval. Hence, chloroquine, hydroxychloroquine, azithromycin, etc., can have a synergistic effect and should be used with caution. Certain protease inhibitors like atazanavir, sequinavir, lopinavir/ritonavir can also cause QTc prolongation. The safer alternatives are lurasidone followed by aripiprazole, olanzapine, and risperidone.

II. Antidepressants
COVID-19 PATIENT WITH HYPOXIA ALONG WITH INCREASED WORK OF BREATHING

MEET CRITERIA FOR MECHANICAL VENTILATION WITH ENDOTRACHEAL INTUBATION

**NO**

- Treat with oxygen supplement therapy with different types of oxygen delivery device in increasing order of FiO2 delivery.
  - O2 concentrator with face mask
  - Nasal cannula
  - O2 cylinder based O2 delivery through face mask, nasal cannula.
  - HFNC/NIV

- Awake proning.
- Other supportive measures.

**YES**

- **Initial Mechanical ventilator setting (Lung protective ventilation)**
  - Tidal Volume (4-6 ml/kg PBW)-allow permissive hypercapnia.
  - PEEP 5-8 Cm H2O (Subsequent change based on compliance and oxygenation)
  - I:E = 1:2 (Consider higher ratio if RR increases > 20/min)
  - RR = 15-20/min
  - If FiO2 > 0.5 (Titrate as per SPO2, can go up to 1.0 in severe hypoxemia)
  - Sedation analgesia target RASS-4

- **If condition deteriorates & Patient meets criteria for intubation**

**If septic shock is also associated with ARDS**

- Consider conservative fluid therapy
- Vasopressor—Nor Adrenaline (1st choice) then Vasopressin and Dobutamine
- Steroids — Hydrocortisone (200 mg/day) and Prednisalone 75 mg/day

**Target of mechanical Ventilation:**

1. Pplat pressure < 30 cm H2O
2. Driving Pressure (∆P) <15cm H2O
3. SpO2 = 90-94%
4. PaO2 >55mmHg
5. P1O2(Occlusion pressure) <3.5cm H2O
6. pH >7.2
7. PaO2/FiO2 >300 mmHg with minimum acceptable PEEP and FiO2
8. Access compliance to differentiate between two phenotypes of COVID 19 pneumonia and adjust PEEP based on phenotypes.

- If Pplat pressure > 30 cm H2O
  - Subsequent ventilatory setting:
    1. Decreased tidal volume to 4-5 ml/kg PBW
    2. Increase RR to maintain minute ventilation.
    3. Maintain pH>7.2
    4. I:E=can change up to 1:1 to ensure more time for inspiration to prevent VILI (Baro trauma)

- Access lung compliance of the patient on mechanical ventilator
  (Compliance >= 40 ml/cm H2O)

**Flow Chart:** flow chart of recommendations on initial ventilatory management of Covid – 19 patients
Citalopram, tricyclic antidepressants, and mirtazapine can prolong QTc interval, which might be augmented when combined with hydroxychloroquine, chloroquine. Escitalopram and sertraline are safer in view of lesser drug interactions and side effects.

III. Mood Stabilisers
Non-steroidal anti-inflammatory drugs (NSAIDs) increase lithium levels, which may lead to toxicity. Valproate levels may be reduced with lopinavir/ritonavir.

IV. Sedatives/hypnotics
Longer acting benzodiazepines like diazepam or clonazepam may be avoided. Lorazepam is preferred as it has the least interaction with antiviral drugs and shorter half-life.

Conclusion
COVID-19 ARDS is an anticipated severe complication of COVID-19 that requires prompt recognition and comprehensive multispeciality management [Flowchart 1]. Extensive research and studies are required to address the vital unanswered queries about treatment for COVID-19 ARDS. Because of the high mortality in mechanically ventilated patients of CARDS, the above recommendations and findings direct the potential for improvement in the management of patients with COVID-19 ARDS.

Ethical approval and consent to participate
Not applicable.

Consent for publication
The authors certify that they have obtained all appropriate permissions for publication.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. World Health Organization. GCM teleconference – Note for the Records. 10 January 2020. Subject: Pneumonia in Wuhan, China. Available from: https://www.who.int/blueprint/10-01-2020-nfr-gcm.pdf. [Last accessed on 2020 Jul 09].
2. Xie F, Ma W, Tang H, Liu D. Severe COVID-19: A review of recent progress with a look toward the future. Front Public Health 2020;8:189. World Health Organization. Teleconference of the R and D Blueprint GCM. 20 January 2020. Pneumonia of unknown etiology in Wuhan China. Available from: https://www.who.int/blueprint/priority-diseases/key-action/20-01-2020-nfr-gcm.pdf?ua=1.
3. World Health Organization. Novel coronavirus (2019-nCoV). Situation Report – 1. 21 January 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.
4. “WHO Coronavirus Disease (COVID-19) Dashboard.” World Health Organization, World Health Organization.
5. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing; 2020.
6. Singh T. A review of coronavirus disease 2019. Indian J Pediatr April 2020;87:281-6.
7. Ferguson, Niall D, et al. "The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material." Intensive care medicine 2012;38:1573-82.
8. Singh, Vijay, et al. "Invasive Mechanical Ventilation of COVID-19 ARDS Patients." Revista Peruana de Investigación en Salud (2021):5:113-26.
9. Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust 2020. doi: 10.5694/mja2.50674.
10. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
11. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 2020;18:1752-5.
12. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): A pictorial review. Eur Radiol 2020;30:4381-9.
13. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet 2020;20:P1135-40.
14. Bai T, Tu, Wei Y, Xiao L, Jin Y, Zhang L, et al. Clinical and laboratory factors predicting the prognosis of patients with COVID-19: An analysis of 127 patients in Wuhan, China. SSRN Electronic J. doi: 10.2139/ssrn.3546118.
15. Yang AP, Liu JR, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020;84:106504. doi: 10.1016/j.intimp.2020.106504.
16. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788–800.
17. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43.
18. Bikkeli, Behnood, et al. "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review." Journal of the American college of cardiology 75.23 (2020): 2950-2973.
19. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raasch S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: A multinational consensus statement from the Fleischner society. Chest 2020;158:106–16.
20. Sun Z, Zhang N, Li Y, Xu X. A systematic review of chest imaging findings in COVID-19. Quant Imaging Med Surg 2020;10:1058-79.
21. Litmanovich DE, Chung M, Kirkbride RR, Kieska G, Kanne JP. Review of chest radiograph findings of COVID-19 pneumonia and suggested reporting language. J Thorac Imaging 2020. doi: 10.1097/RTI.0000000000000541.
61. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020;87:18-22.

62. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.

63. Machado C, DeFina PA, Chinchilla M, Machado Y, Machado Y. Brainstem dysfunction in SARS-CoV2 infection can be a potential cause of respiratory distress. Neuril India 2020;68:989-93.

64. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Targeted Ther 2020;5:84.

65. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291:1753–62.

66. Maldonado JR. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry 2018;33:1428–57.

67. Mascolo A, Berrino PM, Gareri R, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: A review article. Inflammopharmacology 2018;26:1141–9.

68. LaHue SC, James TC, Newman JC, Esmaili AM, Ormseth CH, Ely EW. Collaborative delirium prevention in the age of COVID-19. J Am Geriatr Soc 2020;68:947–9.

69. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: Validation of the confusion assessment method for the intensive care Unit (CAM-ICU). Crit Care Med 2001;29:1370–9.

70. Van Eijk MM, van Marum RJ, Klijn IA, de Wit N, Kesecioglu J, Slooter AJ. Comparison of delirium assessment tools in a mixed intensive care unit. Crit Care Med 2009;37:1881–5.

71. Maldonado JR, Sher YI, Benitez-Lopez MA, Savant V, Garcia R, Ament A, et al. A study of the psychometric properties of the “Stanford proxy test for delirium” (S-PTD): A new screening tool for the detection of delirium. Psychosomatics 2020;61:116–26.

72. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020;250:117583.

73. Dhillon H, Sasidharan S, Dhillon G, Singh V, Babitha M. COVID-19: Neuropsychiatric manifestations and psychopharmacology. Ann Indian Psychiatry 2020;4:226.

74. Kawada K, Ohta T, Tanaka K, Miyamura M, Tanaka S. Addition of suvorexant to ramelteon therapy for improved sleep quality with reduced delirium risk in acute stroke patients. J Stroke Cerebrovasc Dis 2019;28:142–8.

75. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus disease 2019) treatment. Circulation 2020;141:e906–7.

76. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020;583:459–68.

77. Schetz J, Perez E, Liu R, Chen S, Lee I, Simpkins JW. A prototypical sigma-1 receptor antagonist protects against brain ischemia. Brain Res 2007;1181:1–9.

78. Sher Y, Miller Cramer AC, Ament A, Lolak S, Maldonado JR. Valproic acid for treatment of hyperactive or mixed delirium: Rationale and literature review. Psychosomatics 2015;56:615–25.
## COVID-19 Vaccines within WHO EUL/PQ evaluation process

### Guidance Document
63 June 2021

#### APPENDIX 1 : Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

| Manufacturer / WHO EUL holder | Name of Vaccine | NRA of Record | Platform | EDI accepted | Pre-submission meeting held | Dossier accepted for review* | Status of assessment** | Anticipated decision date*** |
|--------------------------------|-----------------|---------------|----------|--------------|-----------------------------|-------------------------------|-------------------------|-----------------------------|
| **1.** | BNTI262/COMIRNATY (mRNA) | EMA | Nucleoside modified mRNA | ✔️ | ✔️ | ✔️ | Finalized | 31/12/20 |
| **2.** | A201222 | EMA | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. | ✔️ | ✔️ | Data for Covax sites expected in April 2021 onwards | Finalized: SK-Calentum Wuxi (US) Chemo Spain | 04 June 2021 |
| **3.** | AD21222 | MFO KOREA | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. | ✔️ | ✔️ | ✔️ | Finalized | 15 Feb 2021 |
| **4.** | CowShield (ChAdOx1 correlate) | DCGI | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. | ✔️ | ✔️ | ✔️ | Finalized | 25 Feb 2021 |
| **5.** | AD26.COV2.5 | EMA | Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the SARS-CoV-2 Spike (S) protein | ✔️ | ✔️ | Core data | Finalized (US-RNA sites) | 12 March 2021 |
| **6.** | mRNA-1273 | EMA | mRNA-based vaccine encapsulated in lipid nanoparticle (LNP) | ✔️ | ✔️ | ✔️ | Finalized | 30 April 2021 |
| **7.** | Sinopharm / BBIBP | NVPA | Inactivated, produced in Vero cells | ✔️ | ✔️ | ✔️ | Finalized | 07 May 2021 |

### COVID-19 Vaccines within WHO EUL/PQ evaluation process

| Manufacturer / WHO EUL holder | Name of Vaccine | NRA of Record | Platform | EDI accepted | Pre-submission meeting held | Dossier accepted for review* | Status of assessment** | Anticipated decision date*** |
|--------------------------------|-----------------|---------------|----------|--------------|-----------------------------|-------------------------------|-------------------------|-----------------------------|
| **8.** | sinovac | SARS-CoV-2 Vaccine (Vero Cell), Inactivated | NVPA | Inactivated, produced in Vero cells | ✔️ | ✔️ | ✔️ | Finalized | 01 June 2021 |
| **9.** | Sputnik V | Russian NRA | Human Adenosine Vector-based SARS-CoV-2 vaccine | Additional information submitted | Several meetings held | Rolling submission after April 2021 | Additional data (Non-CLIN, CLIN, CMC) required | Rolling decision after April 2021 |
| **10.** | Ad5-nCoV | NVPA | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | Rolling data starting June 2021 |
| **11.** | NOVAVAK | NVX-CoV2373 (Covovax) | EMA | Recombinant nanoparticle pre-infection peptide vaccine formulated with Matrix-M™ adjuvant. | 13 June 2021 |
| **12.** | Sinopharm / WIBP | Inactivated | SARS-CoV-2 Vaccine (Vero Cell) | NVPA | Inactivated, produced in Vero Cells | ECO submitted on 30 April and more on 26 May, 2021. | Finalized | 15 July 2021, issued additional information requested. |
| **13.** | Zureccina (RNA) | EMA | mRNA-based vaccine encapsulated in lipid nanoparticle (LNP) | Submitted ECO on 12 April | 13 April |
| **14.** | Bharat Biotech, India | COVAXIN | OCGI | SARS-CoV-2 Vaccine, Inactivated (Vero Cell) | Submitted ECO on 10/04/2021. More information required. | Submitted ECO on 15/04/2021. More information required. | Planned for June 2021 |
| **15.** | Vector State Research Centre of Virusology and Biotechnology | EpiVacCorona | Russian NRA | Peptide antigen | Letter received not EOI. | Letter received on 15/01/2021 |
| **16.** | Zhijin Longcom, China | Recombinant Novel Coronavirus Vaccine (CHO Cell) | NVPA | Recombinant protein subunit | Response to 2nd EOI sent 29 Jan 2021. Additional information requested | Response to 2nd EOI sent 29 Jan 2021. Additional information requested | 2nd EOI sent 29 Jan 2021. Additional information requested |

### COVID-19 Vaccines within WHO EUL/PQ evaluation process

| Manufacturer / WHO EUL holder | Name of Vaccine | NRA of Record | Platform | EDI accepted | Pre-submission meeting held | Dossier accepted for review* | Status of assessment** | Anticipated decision date*** |
|--------------------------------|-----------------|---------------|----------|--------------|-----------------------------|-------------------------------|-------------------------|-----------------------------|
| **17.** | SABCLAMS, China | SARS-CoV-2 Vaccine, Inactivated (Vero Cell) | NVPA | Inactivated | Not accepted, still under initial development |
| **18.** | Clover Biopharmaceuticals | SCB-2019 | EMA | Novel recombinant SARS-CoV-2 Spike (S) fusion protein | In discussion on submission strategy and timelines |
| **19.** | BioCubaFarma - Cuba | Sabinova O2, Sabinova O2, Sabinova Plus ECOVACD | ECO | SARS-CoV-2 spike protein fused covalently to monomeric BSA | | | | | |